|
1
|
Hastie ND: Wilms’ tumour gene and
function. Curr Opin Genet Dev. 3:408–413. 1993.
|
|
2
|
Call KM, Glaser T, Ito CY, et al:
Isolation and characterization of a zinc finger polypeptide gene at
the human chromosome 11 Wilms’ tumor locus. Cell. 60:509–520.
1990.
|
|
3
|
Kreidberg JA, Sariola H, Loring JM, et al:
WT-1 is required for early kidney development. Cell. 74:679–691.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herzer U, Crocoll A, Barton D, Howells N
and Englert C: The Wilms tumor suppressor gene wt1 is required for
development of the spleen. Curr Biol. 9:837–840. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee SB and Haber DA: Wilms tumor and the
WT1 gene. Exp Cell Res. 264:74–99. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mayo MW, Wang CY, Drouin SS, et al: WT1
modulates apoptosis by transcriptionally upregulating the bcl-2
proto-oncogene. EMBO J. 18:3990–4003. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Algar EM, Khromykh T, Smith SI, Blackburn
DM, Bryson GJ and Smith PJ: A WT1 antisense oligonucleotide
inhibits proliferation and induces apoptosis in myeloid leukaemia
cell lines. Oncogene. 12:1005–1014. 1996.PubMed/NCBI
|
|
8
|
Menke AL, Shvarts A, Riteco N, van Ham RC,
van der Eb AJ and Jochemsen AG: Wilms’ tumor 1-KTS isoforms induce
p53-independent apoptosis that can be partially rescued by
expression of the epidermal growth factor receptor or the insulin
receptor. Cancer Res. 57:1353–1363. 1997.
|
|
9
|
Morrison DJ, English MA and Licht JD: WT1
induces apoptosis through transcriptional regulation of the
proapoptotic Bcl-2 family member Bak. Cancer Res. 65:8174–8182.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maheswaran S, Park S, Bernard A, et al:
Physical and functional interaction between WT1 and p53 proteins.
Proc Natl Acad Sci USA. 90:5100–5104. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maheswaran S, Englert C, Zheng G, et al:
Inhibition of cellular proliferation by the Wilms tumor suppressor
WT1 requires association with the inducible chaperone Hsp70. Genes
Dev. 12:1108–1120. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maheswaran S, Englert C, Bennett P,
Heinrich G and Haber DA: The WT1 gene product stabilizes p53 and
inhibits p53-mediated apoptosis. Genes Dev. 9:2143–2156. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vassilev LT, Vu BT, Graves B, et al: In
vivo activation of the p53 pathway by small-molecule antagonists of
MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shangary S and Wang S: Small-molecule
inhibitors of the MDM2-p53 protein-protein interaction to
reactivate p53 function: a novel approach for cancer therapy. Annu
Rev Pharmacol Toxicol. 49:223–241. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee K, Lee MH, Kang YW, Rhee KJ, Kim TU
and Kim YS: Parkin induces apoptotic cell death in TNF-α-treated
cervical cancer cells. BMB Rep. 45:526–531. 2012.PubMed/NCBI
|
|
16
|
Wang Z, Zhang Z, Wu Y, et al: Effects of
echinomycin on endothelin-2 expression and ovulation in immature
rats primed with gonadotropins. Exp Mol Med. 44:615–621. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee SY, Shin SJ and Kim HS: ERK1/2
activation mediated by the nutlin-3-induced mitochondrial
translocation of p53. Int J Oncol. 42:1027–1035. 2013.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Haber DA, Sohn RL, Buckler AJ, Pelletier
J, Call KM and Housman DE: Alternative splicing and genomic
structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA.
88:9618–9622. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Green DR and Kroemer G: The
pathophysiology of mitochondrial cell death. Science. 305:626–629.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao R, Gish K, Murphy M, et al: Analysis
of p53-regulated gene expression patterns using oligonucleotide
arrays. Genes Dev. 14:981–993. 2000.PubMed/NCBI
|
|
22
|
Leu JI, Dumont P, Hafey M, Murphy ME and
George DL: Mitochondrial p53 activates Bak and causes disruption of
a Bak-Mcl1 complex. Nat Cell Biol. 6:443–450. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chipuk JE, Kuwana T, Bouchier-Hayes L, et
al: Direct activation of Bax by p53 mediates mitochondrial membrane
permeabilization and apoptosis. Science. 303:1010–1014. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mihara M, Erster S, Zaika A, et al: p53
has a direct apoptogenic role at the mitochondria. Mol Cell.
11:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vajjhala PR, Macmillan E, Gonda T and
Little M: The Wilms’ tumour suppressor protein, WT1, undergoes
CRM1-independent nucleocytoplasmic shuttling. FEBS Lett.
554:143–148. 2003.
|
|
26
|
Niksic M, Slight J, Sanford JR, Caceres JF
and Hastie ND: The Wilms’ tumour protein (WT1) shuttles between
nucleus and cytoplasm and is present in functional polysomes. Hum
Mol Genet. 13:463–471. 2004.
|
|
27
|
Tovar C, Rosinski J, Filipovic Z, et al:
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in
cancer: implications for therapy. Proc Natl Acad Sci USA.
103:1888–1893. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moreno CS, Matyunina L, Dickerson EB, et
al: Evidence that p53-mediated cell-cycle-arrest inhibits
chemotherapeutic treatment of ovarian carcinomas. PLoS One.
2:e4412007. View Article : Google Scholar : PubMed/NCBI
|
